|
Advertisement
|
|
Home > BioSpectrum TOP 20
| Bharat Serums emphasizes on novel products |
|
|
| Tuesday, June 09, 2009 |
Bharat
Serums emphasizes on novel products
Bharat Serums and
Vaccines manufactures and markets biological, pharmaceutical and
biotechnology products and is now looking at European market
for its expansion.
The past fiscal saw Bharat Serums and Vaccines
(BSV) remaining stable and clocking the same annual revenues of Rs 140
crore for fiscal 2007-08. The company manufactures and markets
biological, pharmaceutical and biotechnology products and has
in its portfolio over 25 brands. Its product range includes plasma
derivatives, monoclonals, equine antitoxins and serums, cardiovascular,
antimicrobials, antifungals, anaesthetics and hormones. Over the years,
BSV has given emphasis to its R&D operations both in
India and overseas. The company has three distinct R&D
divisions working extensively on novel drug delivery system
(NDDS), bioetchnology and equine products.
In 2008, BSV announced that it has developed a novel formulation of
Docetaxel which is free from surfactant Polysorbate-80. This
formulation could potentially be a breakthrough in avoiding the fluid
retention/hypersensitivity and extravasation reactions which are
associated with Taxotere. Initial preclinical studies have shown a
higher safety and a superior pharmacokinetic profile when compared to
Taxotere. Efficacy in tumor bearing mice has also been established for
the newly developed formulation. Taxotere, a branded formulation of
Docetaxel, is marketed by Sanofi Aventis with global sales of more than
Rs 13,624 crore ($2.9 billion). BSV had earlier developed a novel
liposomal formulation of doxorubicin for which it tied up with a
leading Indian pharmaceutical company. Recently, BSV has entered into
licensing agreement with Actavis, one of the world’s leading
generic pharmaceutical companies for an anti-infective product. BSV is
in exploratory discussions with pharmaceutical companies for
collaboration in commercializing the novel formulation of Docetaxel for
various worldwide markets.
BSV, one of the top ten Indian biopharmaceutical companies, has entered
into an exclusive licensing , manufacturing and supply agreement with
Actavis for marketing of one of its anti-infective generic
formulations. Under the terms of the agreement, BSV will develop and
manufacture the product for marketing by Actavis in Europe, Australia,
South Africa and Turkey. The product is a sterile lyophilized injection
that pose significant technological and regulatory challenges. The
total worldwide sales of the product are close to Rs 1,408 crore ($300
million).
BSV and Actavis will be working closely together to obtain the
marketing authorization in Europe and other countries.
Page(s) 1 |
|
|
| |
|
|
|
|
